ESG406 treatment in adults with advanced or metastatic solid tumors
Official title: An Open-Label, Multiple Dose, Dose Escalation and Cohort Expansion Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of ESG406 in Subjects With Locally Advanced/Metastatic Solid Tumors
Run by Shanghai Escugen Biotechnology Co., Ltd · NCT06979674 · Data updated 2026-11-12
This Phase 1 study will test whether ESG406 is safe and shows early signs of benefit in adults with advanced or metastatic solid tumors who have no standard treatment options.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 556 (estimated) |
| Sponsor | Shanghai Escugen Biotechnology Co., Ltd Industry-sponsored |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 3 sites (Chongqing, Chongqing Municipality and 2 other locations) |
| Status | Recruiting |
| Started | June 4, 2025 |
| Main results expected | April 2028 |
| Study ends | June 2028 |
| Registry record updated | September 12, 2025 |
| Trial ID | NCT06979674 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18–80 with confirmed locally advanced or metastatic solid tumors, measurable disease, ECOG performance status 0–1, adequate organ and marrow function, and no effective standard therapy available are the intended candidates.
✕Probably not a fit
Patients who recently received systemic cancer therapy (within 4 weeks), have unresolved treatment toxicities, poor performance status, or inadequate organ function are unlikely to qualify and therefore may not benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This open‑label Phase Ia/Ib study uses a dose‑escalation phase followed by cohort expansion to define the maximum tolerated dose and recommended Phase 2 dose and to explore administration schedules for ESG406. Primary objectives include characterizing safety, tolerability and pharmacokinetics; secondary objectives include preliminary anti‑tumor activity. Eligible participants are adults (18–80 years) with histologically or cytologically confirmed locally advanced or metastatic solid tumors, measurable disease by RECIST v1.1, ECOG 0–1, and adequate organ function. Key exclusions include receipt of systemic anticancer therapy within 4 weeks or unresolved toxicities from prior treatments.
Why it matters
Potential benefit: If successful, the study could identify a safe dose and schedule of ESG406 and show early signs of tumor control that would support larger trials.
How similar studies have gone: Phase I dose‑escalation and cohort‑expansion designs have enabled other novel anticancer agents to find safe doses and sometimes show early responses, but ESG406 itself is a novel investigational agent without reported late‑stage success to date.
Who can join: the full rules
Show full inclusion / exclusion criteria
Key Inclusion Criteria: * Males and females aged 18 to 80 years. * Histologically or cytologically confirmed advanced or metastatic solid tumor(s) for which no effective standard therapy is available or tolerable. * At least one measurable lesion per RECIST v1.1. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Life expectancy ≥12 weeks. * Adequate organ and bone marrow function. * Fertile men and women of childbearing potential must agree to use an effective method of birth control from providing signed consent and for 180 days after last investigational product administration. Women of childbearing potential include pre-menopausal women and women within the first 2 years of the onset of menopause. Key Exclusion Criteria: * Use of any cancer therapy (chemotherapy or other systemic anti-cancer therapies, immunotherapy) within 4 weeks before the first investigational product administration. * Toxicities from prior anti-tumor therapy not recovering to ≤ Grade 1. * Had major surgery within 4 weeks before dosing, or will not have fully recovered from surgery; or has surgery planned during the time the subject is expected to participate in the study or within 4 weeks after the last dose of study drug administration. * Use of any investigational anti-cancer drug within 4 weeks or 5 half-lives before the first investigational product administration. * A history of thromboembolic or cerebrovascular events within 6 months prior to the first dose of the investigational drug. * History of (noninfectious) interstitial pneumonia (ILD)/noninfectious pneumonitis requiring steroid therapy and current ILD/noninfectious pneumonitis, or suspected ILD/noninfectious pneumonitis at screening. * Subjects with symptomatic or untreated CNS metastases, or those requiring ongoing treatment for CNS metastases. * Patients with Primary CNS malignancy, or patients with other malignancies within 3 years prior to the first dose. * Patients with uncontrollable systemic diseases. * Subjects with clinically significant cardiovascular disease. * Human Immunodeficiency Virus (HIV) infection. * Active hepatitis B or hepatitis C. * Have an allergic constitution, or to be allergic to any investigational drug or excipient ingredient. * Pregnant or lactating women.
Where it's running
-
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, China Recruiting -
The First Affiliated Hospital of Xi 'An Jiaotong University
Xi’an, Shanxi, China Recruiting -
The Second Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China Recruiting
Study contacts
- Principal investigator: Fuming Qiu, PhD — Second Affiliated Hospital, Zhejiang University, School of Medicine
- Study coordinator: Xiaoyan Xing, PhD
- Email: xingxiaoyan@escugen.com
- Phone: +86 21 5855 6098
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Testing ISM3412 for advanced solid tumors with specific genetic markers
This study is testing a new drug called ISM3412 to see if it can help people with advanced solid tumors that have specific genetic markers and who haven't had success with other treatments.
-
Injection of PE0116 and PE0105 for advanced solid tumors
This study is testing two new injections, PE0116 and PE0105, to see if they can help people with advanced solid tumors that haven't responded to other treatments.
-
Evaluating ESG206 for treating primary immune thrombocytopenia
This study is testing a new treatment called ESG206 to see if it can safely help people with primary immune thrombocytopenia improve their condition.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.